The Dual-Organ Problem: How SERPINA1 Mutations Drive Liver and Lung Disease

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder caused by mutations in the SERPINA1 gene that simultaneously damages two organ systems through two distinct mechanisms. The most common mutation — the PiZ variant (E342K) — causes the AAT protein to misfold and accumulate as polymers inside hepatocytes, triggering chronic liver disease, while the resulting shortage of functional AAT in the bloodstream leaves pulmonary tissue exposed to unchecked neutrophil elastase activity.

Alpha-1 antitrypsin (AAT) is a serine protease inhibitor encoded by SERPINA1. Its primary role is to inhibit neutrophil elastase and other proteases, protecting lung tissue from degradation. In individuals carrying two copies of the PiZ allele — the PiZZ genotype — the protein’s tertiary structure is disrupted by the E342K substitution. Rather than being secreted normally, the misfolded Z-AAT protein forms intracellular polymer chains that accumulate within hepatocytes. This accumulation drives cellular stress, inflammation, and progressive liver fibrosis. Simultaneously, the lungs receive far less functional AAT than they require, creating a permissive environment for elastase-driven emphysema.

Historical treatments focused exclusively on the pulmonary dimension: augmentation therapy delivers purified AAT protein intravenously to restore elastase inhibitory capacity in the lung. While augmentation therapy slows lung function decline according to studies referenced by NIH, it does nothing to address the toxic polymer accumulation in the liver — the root cause of hepatic disease progression. This therapeutic gap is precisely what the emerging pipeline of RNAi agents and gene therapies is designed to close.

Fazirsiran and GalNAc Delivery: The RNAi Strategy Targeting Hepatocytes

Fazirsiran — previously known as ARO-AAT and developed by Arrowhead Pharmaceuticals — works by silencing SERPINA1 mRNA in hepatocytes before the misfolded protein can be produced, using RNA interference delivered via a hepatocyte-targeting conjugate. The drug consists of an RNAi agent comprising a guide strand complementary to SERPINA1 mRNA and a passenger strand that together form a double-stranded region, which is then conjugated to an N-acetylgalactosamine (GalNAc) moiety.

GalNAc — N-acetylgalactosamine — binds with high affinity to the asialoglycoprotein receptor (ASGPR) that is highly expressed on the surface of hepatocytes. This receptor-mediated targeting is what makes subcutaneous administration viable: the GalNAc moiety directs the RNAi payload specifically to liver cells, achieving high local concentrations at the site of SERPINA1 expression while minimising off-target exposure. The approach is consistent with broader developments in GalNAc-conjugated therapeutics documented in the literature on RNA interference, including work published in Nature.

“Fazirsiran is conjugated to N-acetylgalactosamine (GalNAc) for targeted hepatocyte delivery — enabling a subcutaneous injection every 12 weeks to silence the mutant SERPINA1 gene at its source.”

Arrowhead Pharmaceuticals’ patent portfolio, filed under multiple patent families with a priority date of August 2024, covers both the GalNAc-conjugated RNAi compositions and their methods of use. The claims explicitly cover methods of reducing liver fibrosis, reducing liver inflammation, reducing cellular stress and liver injury associated with AATD, and preventing or reducing the risk of pulmonary disease associated with AATD. Compositions may also include lipid nanoparticles as an alternative delivery vehicle.

Phase 2 Evidence: What the AROAAT2002 Trial Demonstrated

The AROAAT2002 Phase 2 trial established the clinical proof-of-concept for fazirsiran in patients with the most severe form of AATD-associated liver disease, showing significant reductions in Z-AAT polymer burden and histological improvement across a substantial proportion of treated participants. The trial enrolled adults with the PiZZ genotype who had a histologically confirmed diagnosis of liver fibrosis or cirrhosis — the population at greatest risk of progressive hepatic decompensation.

Participants received subcutaneous injections of 100 mg fazirsiran or placebo every 12 weeks for 48 weeks. The primary findings reported by Strnad, Mandorfer, Choudhury and colleagues in the published Phase 2 report were that fazirsiran reduced Z-AAT hepatic polymer load and improved liver histology in a substantial proportion of patients. Biochemical evidence published separately by Teckman and Jain confirmed significant reduction in liver fibrosis scores, ALT normalisation, and reduction of Z-AAT polymer accumulation. These results were described as supporting progression to Phase 3 trials.

The significance of the histological endpoints in AROAAT2002 cannot be overstated. Liver biopsy-based assessment of fibrosis stage is the gold standard for evaluating disease-modifying activity in chronic liver disease, and demonstrating histological improvement — rather than merely biochemical change — is the threshold regulators typically require for approval in this indication. The trial’s design, enrolling only patients with confirmed fibrosis or cirrhosis, positioned fazirsiran squarely in the highest-need segment of the AATD population.

Beyond RNA Silencing: Gene Editing and the Path to Phase 3

Arrowhead Pharmaceuticals’ intellectual property in AATD extends beyond RNAi to encompass gene-editing approaches that target the SERPINA1 gene itself, representing a potential route to more durable therapeutic correction than mRNA-level silencing alone can achieve. The company’s patent filings describe recombinant nucleic acids encoding gene-editing components that directly edit the SERPINA1 gene — a mechanistically distinct strategy from the RNA interference approach used in fazirsiran.

Where RNAi therapeutics such as fazirsiran act at the mRNA level — silencing the transcript produced by the mutant gene — gene-editing approaches operate at the DNA level, aiming to correct or permanently disrupt the pathogenic PiZ allele. This distinction matters clinically: RNAi requires repeated dosing to maintain silencing (hence the every-12-weeks regimen), whereas a successful gene edit could theoretically provide permanent correction from a single treatment. The field of gene therapy for inherited liver diseases has been tracking this trajectory, with regulatory bodies including the European Medicines Agency increasingly engaged with gene therapy submissions for rare genetic disorders.

The patent claims filed by Arrowhead Pharmaceuticals cover methods of treating diseases caused by AATD using both RNAi compositions and gene-editing components, as well as specific methods of reducing liver fibrosis, reducing liver inflammation, and reducing cellular stress and liver injury associated with AATD. The dual coverage — RNA interference and gene editing — signals a platform strategy rather than a single-asset bet, with the company protecting multiple mechanistic pathways to address the same underlying genetic defect.

Lipid nanoparticles (LNPs) are also covered as an alternative delivery vehicle in the Arrowhead filings, alongside the GalNAc conjugation approach used in fazirsiran. LNPs have become the dominant delivery system for nucleic acid therapeutics following the clinical validation achieved by mRNA COVID-19 vaccines, and their inclusion in the AATD patent portfolio suggests potential future formulation flexibility — particularly relevant for gene-editing payloads that may be too large or structurally incompatible with GalNAc conjugation.

Patent Landscape: Arrowhead Pharmaceuticals and the IP Architecture of AATD

The AATD therapeutic patent landscape is currently dominated by Arrowhead Pharmaceuticals, whose multiple patent families — all sharing a priority date of August 2024 — construct a broad IP perimeter around GalNAc-conjugated RNAi agents targeting SERPINA1 and gene-editing approaches to the same gene. Understanding the architecture of this IP estate is essential for any organisation evaluating entry into the AATD space, whether as a competitor, collaborator, or licensor.

The core patent claims from Arrowhead Pharmaceuticals cover: RNAi agents with a guide strand complementary to SERPINA1 mRNA and a passenger strand forming a double-stranded region; conjugation to GalNAc targeting ligands for hepatocyte delivery; recombinant nucleic acids encoding gene-editing components that edit the SERPINA1 gene; and lipid nanoparticle formulations. The breadth of these claims — spanning delivery chemistry, nucleic acid design, and gene-editing modalities — creates a substantial freedom-to-operate challenge for potential competitors.

The historical treatment landscape, as documented in earlier literature by Sandhaus and Turino, had already identified gene therapy and RNA-based silencing as the emerging strategic directions for AATD. The patent activity now observed from Arrowhead Pharmaceuticals represents the maturation of those research directions into protectable, clinically tested assets. For IP professionals and R&D leaders evaluating the AATD space, the convergence of strong Phase 2 clinical data with a broad patent estate — all centred on Arrowhead Pharmaceuticals — defines the competitive dynamics of the next phase of development. Standards for clinical development in rare genetic liver diseases are also shaped by guidance from regulatory bodies including the FDA and patent classification systems maintained by the European Patent Office.

The PatSnap Life Sciences platform enables teams to map competitor patent filings, identify white spaces in the AATD IP landscape, and monitor new filings as the pipeline moves toward Phase 3 registration trials. With the PatSnap drug discovery intelligence module, R&D teams can also track clinical trial registrations, regulatory filings, and publication activity across the entire AATD therapeutic space.